Argenx Se (ARGX) Receivables - Net (2015 - 2026)
Argenx Se (ARGX) posted quarterly Receivables - Net of $1.9 billion for Q2 2026, down 99.84% year-on-year from $1197.1 billion in Q2 2025, and up 17.24% on a QoQ basis from $1.6 billion in Q4 2025.
Argenx Se (ARGX) Receivables - Net (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Receivables - Net for 12 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.
- Quarterly Receivables - Net fell 99.84% year-over-year to $1.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 billion (down 99.84% YoY) and the FY2025 annual result came in at $1.6 billion, up 82.1% from the prior year.
- Receivables - Net improved to $1.9 billion in Q2 2026 per ARGX's latest filing, from $1.6 billion in the prior quarter.
- Over the last five years, Receivables - Net for ARGX reached as high as $1197.1 billion in Q2 2025 and fell as low as $112.4 million in Q2 2022.
- A 5-year average of $133.7 billion and a median of $652.9 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2025 — Receivables - Net jumped 183253.63% — and 2026, when it sank 99.84%.
- Year by year, Receivables - Net stood at $275.7 million in 2022, then soared by 80.16% to $496.7 million in 2023, then soared by 82.1% to $904.5 million in 2024, then surged by 82.1% to $1.6 billion in 2025, then increased by 17.24% to $1.9 billion in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $1.9 billion, $1.6 billion, and $1197.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Bn |
| Jun 30, 2026 | 1.93 Bn |
| Dec 31, 2025 | 1.65 Bn |
| Dec 31, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1,197.07 Bn |
| Jun 30, 2025 | 1,197.07 Bn |
| Dec 31, 2024 | 904.47 Mn |
| Dec 31, 2024 | 904.47 Mn |
| Jun 30, 2024 | 652.88 Mn |
| Jun 30, 2024 | 652.88 Mn |
| Dec 31, 2023 | 496.69 Mn |
| Dec 31, 2023 | 496.69 Mn |
| Jun 30, 2023 | 353.23 Mn |
| Jun 30, 2023 | 353.23 Mn |
| Dec 31, 2022 | 275.70 Mn |
| Dec 31, 2022 | 275.70 Mn |
| Jun 30, 2022 | 112.39 Mn |
| Jun 30, 2022 | 112.39 Mn |
| Dec 31, 2021 | 38.22 Mn |
| Dec 31, 2021 | 38.22 Mn |